What is the current Price Target for the Vivos Therapeutics Inc stock?

The average Vivos Therapeutics Inc target price is $5.50. This is 115.69% higher than the current stock price. 1 Analyst has issued a Vivos Therapeutics Inc price target 2026.

How high will the Vivos Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Vivos Therapeutics Inc stock will rise. The performance of stocks, including the Vivos Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Vivos Therapeutics Inc stock today?

The performance of Vivos Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Vivos Therapeutics Inc stock fall?

The decline in Vivos Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Vivos Therapeutics Inc Forecast, price target & analysts

$2.57

0.00% day before yesterday

Nasdaq, Apr 04, 09:14 pm CET

ISIN

US92859E1082

Symbol

VVOS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Vivos Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Vivos Therapeutics Inc Classifications & Recommendation:

Buy

100%

Vivos Therapeutics Inc Price Target

Target Price	$5.50
Price	$2.55
Potential	115.69% register free of charge
Number of Estimates	1

	1 Analyst has issued a Vivos Therapeutics Inc price target 2026. The average Vivos Therapeutics Inc target price is $5.50. This is 115.69% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 1 Analysts recommend Vivos Therapeutics Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Vivos Therapeutics Inc stock has an average upside potential 2026 of 115.69% register free of charge . Most analysts recommend the Vivos Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Revenue Million $	15.03	18.00
	8.91%	19.76%

1 Analyst has issued a sales forecast Vivos Therapeutics Inc 2025 . The average Vivos Therapeutics Inc sales estimate is

Unlock

. This is

Unlock

than the revenue of the last 12 months(TTM). The highest sales forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics:

2024	$15.0m	8.91%
2025	$18.0m 19.76% Unlock
2026	$22.7m 26.27% Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
EV/Sales		0.57

Based on analysts' sales estimates for 2025, the Vivos Therapeutics Inc stock is valued at an EV/Sales of

Unlock

and an P/S ratio of

Unlock

This results in the following potential growth metrics and future valuations:

Current	0.68	38.78%
2025	0.57 16.09% Unlock
2026	0.45 20.80% Unlock

Current	1.00	114.49%
2025	0.83 16.50% Unlock
2026	0.66 20.81% Unlock

Vivos Therapeutics Inc...

Current Vivos Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Ascendiant Capital	Locked ➜ Locked	Locked	Nov 20 2024
Alliance Global Partners	Locked ➜ Locked	Locked	Nov 19 2024
Ascendiant Capital	Locked ➜ Locked	Locked	Aug 20 2024

Analyst Rating	Date
Locked Ascendiant Capital: Locked ➜ Locked	Nov 20 2024
Locked Alliance Global Partners: Locked ➜ Locked	Nov 19 2024
Locked Ascendiant Capital: Locked ➜ Locked	Aug 20 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 95.20%

BioNTech SE - ADR 57.25%

Amazon.com 55.96%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now